Rotigotine Discount Agreement (Open-House)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Rotigotin (ATC-Code nach WHO: N04BC09)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No minimum quantities guaranteed; actual sales depend on unpredictable prescribing and dispensing patterns.
The buyer may terminate the Open-House if exclusive agreements are signed, which typically happen 8-12 months after pub...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 31, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Supply of pharmaceutical products with active substance Rotigotine (ATC N04BC09)
- Conclusion of a non-exclusive discount agreement under §130a Abs. 8 SGB V
Show full summary
This is a non-exclusive discount agreement (Rabattvereinbarung) for the active substance Rotigotine (ATC N04BC09), conducted as an Open-House model by AOK PLUS. The agreement is open to all interested pharmaceutical companies meeting the requirements, with no exclusivity and no guaranteed minimum purchase quantities. The procedure is not a formal public procurement but published for transparency. Participation is possible from the first deadline (03.12.2024) until the agreement ends (31.12.2026). The estimated contract value is not specified.
Risks
No minimum quantities guaranteed; actual sales depend on unpredictable prescribing and dispensing patterns.
The buyer may terminate the Open-House if exclusive agreements are signed, which typically happen 8-12 months after pub...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG
- Must have a registered seat in Germany, EU/EEA
Eligibility
- Must submit declaration of no exclusion grounds (§§123,124 GWB) and Russia sanctions compliance
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Rotigotine Discount Agreement (Open-House)
Non-exclusive discount agreement for Rotigotine (N04BC09) under §130a Abs. 8 SGB V, open to all qualified pharmaceutical companies. No minimum volume, no exclusive supply. Agreement ends 31.12.2026.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Rotigotin (ATC-Code nach WHO: N04BC09)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 10 Nov 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 684657-2024
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No minimum quantities guaranteed; actual sales depend on unpredictable prescribing and dispensing patterns.
The buyer may terminate the Open-House if exclusive agreements are signed, which typically happen 8-12 months after pub...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications